Published On: Wed, Oct 19th, 2016

New Analyst Ratings On Innocoll AG (INNL)


Recently stock market analysts have updated their consensus ratings on shares of Innocoll AG (INNL).

Most recent broker ratings

06/30/2016 – Innocoll AG had its “outperform” rating reiterated by analysts at FBR Capital Markets. They now have a USD 18 price target on the stock.

04/28/2016 – Janney Montgomery Scott began new coverage on Innocoll AG giving the company a “buy” rating. They now have a USD 15 price target on the stock.

05/18/2015 – Innocoll AG was upgraded to “buy” by analysts at Zacks. They now have a USD 11 price target on the stock.

08/19/2014 – Piper Jaffray began new coverage on Innocoll AG giving the company a “overweight” rating. They now have a USD 14 price target on the stock.

08/19/2014 – Stifel Nicolaus began new coverage on Innocoll AG giving the company a “buy” rating. They now have a USD 18 price target on the stock.

08/19/2014 – JMP Securities began new coverage on Innocoll AG giving the company a “market outperform” rating. They now have a USD 18 price target on the stock.

Innocoll AG has a 50 day moving average of 6.03 and a 200 day moving average of 6.84. The stock’s market capitalization is 146.85M, it has a 52-week low of 4.57 and a 52-week high of 13.72.

The share price of the company (INNL) was down -0.82% during the last trading session, with a high of 6.26 and the volume of Innocoll AG shares traded was 150859.

Innocoll Holdings Public Limited Company is a commercial-stage specialty pharmaceutical and medical device company with late-stage development programs. The Company operates through the segment of manufacture and sale of collagen-based pharmaceutical products. It utilizes collagen-based technology platform to develop its biodegradable and bioresorbable products and product candidates, which can be broken down by the body without the need for surgical removal or applied topically. Using its processes at its manufacturing facility, it derives and purifies bovine and equine collagen and then utilizes its technology platform to incorporate the purified collagen into its topical and implantable products. Its lead product candidates are XaraColl for the treatment of post-operative pain and Cogenzia for the treatment of diabetic foot infections. Its marketed products include CollaGUARD, Collatamp, Septocoll and RegenePro. It has initiated its Phase III efficacy trials for Cogenzia.